SCHEMBL27134473

SCHEMBL27134473

CC(=O)Nc1ccccc1C(=O)Nc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.77
MEN1 O00255 3/20 0.77
SMN1; SMN2 Q16637 4/20 0.71
NPC1 O15118 4/20 0.71
RAB9A P51151 4/20 0.71
RXFP1 Q9HBX9 1/20 0.65
CYP2C19 P33261 3/20 0.64
POLB P06746 3/20 0.64
HTT P42858 2/20 0.62
RECQL P46063 1/20 0.62
HSD17B10 Q99714 2/20 0.62
NAPRT Q6XQN6 1/20 0.62
HPGD P15428 2/20 0.61
ALDH1A1 P00352 2/20 0.59
CYP1A2 P05177 1/20 0.58
ALPL P05186 1/20 0.58
ALPI P09923 1/20 0.58
ALPG P10696 1/20 0.58
CYP2C9 P11712 1/20 0.58
KDM4E B2RXH2 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11783963 0.90 MEN1 (0.68) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL25063018 0.88 KMT2A (0.66) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL6815864 0.87 MEN1 (0.64) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL30142676 0.87 MEN1 (0.64) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL30142859 0.87 POLB (0.71) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL24073684 0.87 SMN1; SMN2 (0.74) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL24073679 0.87 KMT2A (0.64) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL24073672 0.87 MEN1 (0.64) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL24074064 0.87 POLB (0.71) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL10801453 0.87 KMT2A (0.60) KMT2AMEN1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 KMT2A 1342/4885MEN1 3254/4885SMN1; SMN2 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.